[EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2017060854A1
公开(公告)日:2017-04-13
The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
[EN] N-ARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] N-ARYL PYRAZOLES EN TANT QUE RÉGULATEURS DE NRF2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2018109642A1
公开(公告)日:2018-06-21
The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators. In particular, the compounds of this invention include a compound of Formula (I).
[EN] NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS<br/>[FR] NOUVELLES PYRIDINONES BICYCLIQUES UTILISÉES COMME MODULATEURS DE GAMMA-SÉCRÉTASE
申请人:PFIZER
公开号:WO2015049616A1
公开(公告)日:2015-04-09
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
所述化合物及其药用可接受的盐已被披露,其中这些化合物具有规范中定义的 Formula I 的结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS
申请人:PFIZER INC.
公开号:US20160229847A1
公开(公告)日:2016-08-11
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Free-radical functionalisation of β-amino alcohols via 1,5-hydrogen atom abstraction in 1,3-oxazolidines
作者:Rajendra Gosain、Andrew M. Norrish、Mark E. Wood
DOI:10.1016/s0040-4039(99)01344-1
日期:1999.9
Functionalisation of ethanolamine at the carbon atom ob to nitrogen can be achieved in a diastereoselective C-4 alkylation of 1,3-oxazolidines using free-medical methodology. (C) 1999 Elsevier Science Ltd. All rights reserved.